/MAIA
MAIA Stock - MAIA Biotechnology, Inc.
Healthcare|BiotechnologyAMEX
$1.22+1.67%
+$0.02 (+1.67%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.34
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MAIA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.21 – $1.23
TARGET (TP)$1.40
STOP LOSS$1.12
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.01
52W High$2.74
52W Low$0.87
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-16,957,210 | $-20,182,381 | $-16,176,201 | $-7,786,627 | $-6,975,601 |
| Net Income | $-23,254,656 | $-19,772,905 | $-15,769,279 | $-12,503,880 | $-6,636,660 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.05 | $-1.49 | $-1.70 | $-1.18 | $-0.62 |
Company Overview
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MAIABeat Rate
67%
Last 12 quarters
Avg Surprise
+7.5%
EPS vs Estimate
Beats / Misses
8/4
Last 12 quarters
Latest EPS
$-0.27
Q4 2025
EPS Surprise History
Q1 24
-17.1%
$-0.41vs$-0.35
Q2 24
-39.4%
$-0.46vs$-0.33
Q3 24
+48.5%
$-0.17vs$-0.33
Q4 24
+65.6%
$-0.11vs$-0.32
Q1 25
+15.0%
$-0.17vs$-0.20
Q2 25
+11.1%
$-0.16vs$-0.18
Q3 25
+25.0%
$-0.18vs$-0.24
Q4 25
-42.1%
$-0.27vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 20, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.19 | $-0.27 | -42.1% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.24 | $-0.18 | +25.0% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q1 2025 | Mar 21, 2025 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.32 | $-0.11 | +65.6% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.33 | $-0.17 | +48.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.33 | $-0.46 | -39.4% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.38 | $-0.36 | +5.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.43 | $-0.35 | +18.6% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.40 | $-0.38 | +5.0% | ✓ BEAT |
Q1 2023 | Mar 24, 2023 | $-0.41 | $-0.43 | -4.9% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | — | $-0.49 | — | — |
Q3 2022 | Aug 8, 2022 | — | $-0.31 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-0.32 | — | — |
Q2 2022 | Apr 11, 2022 | — | $-0.27 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.49 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.32 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.09 | — | — |
Latest News
MAIA Biotechnology Announces $1.51M Private Placement Of 1.23M At A Price Of $1.224/Share With Warrants Exercisable At A Price Of $1.36/Share
➖ NeutralBenzinga•Dec 16, 2025, 09:18 PM
MAIA Biotechnology Doses First Patient In Phase 3 Trial Of Ategenosine Plus Checkpoint Inhibitor For Advanced NSCLC
📈 PositiveBenzinga•Dec 11, 2025, 02:10 PM
MAIA Biotechnology Makes Open-Market Purchases: CEO Buys 94,300 Shares At An Average Price Of $1.08/Share; Board Members Acquire 88,145 Shares At An Average Price Of $1.04/Share, Totaling 182,445 Shares Combined
📈 PositiveBenzinga•Dec 1, 2025, 02:20 PM
MAIA Biotechnology Highlights Phase 2 THIO‑101 Expansion And Phase 3 THIO‑104 Trials Of Telomere Targeting Agent Ateganosine For NSCLC At SITC 2025; FDA Grants Fast Track Designation
📈 PositiveBenzinga•Nov 21, 2025, 02:05 PM
MAIA Biotechnology Presents Trial In Progress Poster At 2025 AACR-NCI-EORTC Conference; Co. Enrolls Five Patients From Taiwan And Turkey In Expansion Phase Of THIO-101 Phase 2 Trial
➖ NeutralBenzinga•Oct 27, 2025, 02:54 PM
MAIA Biotechnology Reports Efficacy Of Ateganosine In High-Risk Non-Small Cell Lung Cancer At ESMO 2025
📈 PositiveBenzinga•Oct 23, 2025, 12:38 PM
MAIA Biotechnology Announces $736,600 Private Placement Of 603,769 Shares At $1.22/Share
➖ NeutralBenzinga•Oct 13, 2025, 08:21 PM
MAIA Biotechnology adopts crypto treasury strategy; shares up
📈 PositiveSeeking Alpha•Oct 7, 2025, 01:05 PM
MAIA Biotechnology Authorizes Up To 90% Of Liquid Assets In Bitcoin, Ethereum, And USD Coin For New Digital Treasury Strategy
📈 PositiveBenzinga•Oct 7, 2025, 12:49 PM•Also: , ,
MAIA Biotechnology Announces $2.25M Private Placement Of 1,733,766 Shares At Purchase Price Of $1.30/Share
➖ NeutralBenzinga•Sep 29, 2025, 08:30 PM
MAIA Biotechnology Receives $2.3M NIH Grant To Expand THIO-101 Phase 2 Trial For Advanced Lung Cancer In U.S.
📈 PositiveBenzinga•Sep 24, 2025, 12:04 PM
MAIA Biotechnology Highlights Efficacy Data From Phase 2 Clinical Trial, THIO-101, Evaluating Ateganosine Sequenced With Immune CPI Cemiplimab In Patients With Advanced NSCLC
📈 PositiveBenzinga•Sep 11, 2025, 01:29 PM
MAIA Biotechnology To Present Phase 2 THIO + Cemiplimab Data In ICI-Resistant aNSCLC At IASLC WCLC 2025; Poster Highlights PFS Improvement
📈 PositiveBenzinga•Sep 5, 2025, 01:05 PM
MAIA Biotechnology shares are trading higher after the company published its Phase 2 THIO-101 trial developments.
📈 PositiveBenzinga•Aug 27, 2025, 07:34 PM
MAIA Biotechnology's Phase 2 THIO-101 Trial Developments Published In Cells Journal
📈 PositiveBenzinga•Aug 27, 2025, 01:07 PM
Frequently Asked Questions about MAIA
What is MAIA's current stock price?
MAIA Biotechnology, Inc. (MAIA) is currently trading at $1.22 per share. The stock has moved +1.67% today.
What is the analyst price target for MAIA?
No analyst price targets are currently available for this stock.
What sector is MAIA Biotechnology, Inc. in?
MAIA Biotechnology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is MAIA's market cap?
MAIA Biotechnology, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does MAIA pay dividends?
No, MAIA Biotechnology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
CALC
CalciMedica, Inc.
$6.35
Mkt Cap: $0.1B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
ELUT
Elutia Inc.
$0.59
Mkt Cap: $0.0B
LTRN
Lantern Pharma Inc.
$3.26
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
RNXT
RenovoRx, Inc.
$0.93
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
VERU
Veru Inc.
$2.32
Mkt Cap: $0.0B
Explore stocks similar to MAIA for comparison